ChemedFRA:CXM +1.04%75 Net Margin % is 10.08% as of Mar. 2026, which is 13% below its 10-year median of 11.61. GuruFocus rates FRA:CXM with a GF Score™ of 75/100 and a GF Value™ of €566.42 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Chemed ranks better than 78.29% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Chemed's Net Income for the
three
months ended in Mar. 2026 was €57 Mil. Chemed's Revenue for the
three
months ended in Mar. 2026 was €569 Mil. Therefore, Chemed's net margin for the quarter that ended in Mar. 2026 was 10.08%.
The historical rank and industry rank for Chemed's Net Margin % or its related term are showing as below:
FRA:CXM'
s Net Margin % Range Over the Past 10 Years
Min: 5.89 Med: 11.61 Max: 15.36
Current: 10.23
FRA:CXM's Net Margin % is ranked better than 78.29% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs FRA:CXM: 10.23
Chemed (FRA:CXM) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Chemed Net Margin % Related Terms
Chemed Net Margin % Historical Data
* Premium members only.
The historical data trend for Chemed's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CXM vs PACS, OPCH, CON: Net Margin % Comparison
For the Medical Care Facilities subindustry, Chemed's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemed Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Chemed's Net Margin % distribution charts can be found below:
* The bar in red indicates where Chemed's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemed (FRA:CXM) has a Net Margin % of 10.08% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Chemed and its competitors. This is 13% below median its historical median of 11.61. Over the past decade, Chemed's Net Margin % has ranged from 5.89 to 15.36. According to the industry distribution chart, Chemed ranks #145 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 21.7%.
Is Chemed's Net Margin % too high?
Chemed's current Net Margin % of 10.08% is 13% below median its 10-year median of 11.61. Over the past 10 years, this metric has ranged from a low of 5.89 to a high of 15.36. The Healthcare Providers & Services industry median Net Margin % is 2.89. Chemed's value of 10.08% is 249.4% above this industry median. Based on the distribution chart, Chemed ranks #145 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Chemed has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's Net Margin % compare to PACS and OPCH?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #145 out of 668 companies for Net Margin %. This places Chemed in the top 22% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.89. Chemed's value of 10.08% is 249.4% above this benchmark. Historically, Chemed's own Net Margin % has ranged from 5.89 to 15.36 over the past decade. While the company's 10-year median is 11.61 vs. the industry median of 2.89, Chemed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemed's current Net Margin % of 10.08% is 249.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Chemed and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemed's current Net Margin % is 10.08%, which is 13% below median its own 10-year median of 11.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Significantly Undervalued. The stock's GF Value™ is €566.42, compared to a current price of €390.00 — trading 31.1% below its estimated fair value. The current Net Margin % is 10.08%, which is 13% below median its 10-year median of 11.61 and 249.4% above the Healthcare Providers & Services industry median of 2.89. Chemed's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Chemed (FRA:CXM), the current Net Margin % is 10.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemed (FRA:CXM) Overvalued in 2026?
Based on GuruFocus' analysis, Chemed stock appears to be undervalued.
The current stock price of €390.00 is trading 31.1% below its estimated GF Value™ of €566.42.
GuruFocus considers Chemed to be Significantly Undervalued.
Key valuation signals for FRA:CXM:
Net Margin %: 10.08% (13% below median its 10-year median of 11.61)
GF Value™: €566.42 vs. price of €390.00 (31.1% below fair value)
Industry Position: 249.4% above the Healthcare Providers & Services median (#145 of 668)
No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
75GF Score
Get the complete analysis for FRA:CXM
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CXM has been successfully added to your 
